Most GLP-1s are approved only for adults 18 and older
Because tirzepatide produces more weight loss than semaglutide (dual receptor versus single receptor), and because orforglipron is a single GLP-1 receptor agonist, there was an expected gap in potency
After 6 months of TNFi therapy, two different metabolic profiles separated good responders from non-responders, and carbohydrate derivates (D-glucose, D-fructose, sucrose, and maltose) emerged as determinants of the therapeutic response
For now, researchers say the results offer a promising signal
When approaching the security checkpoint, inform the security officer immediately that you are carrying medical injections, needles, and associated supplies
(2004) 286:G4918